Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastiaan Engelborghs

Showing results (251-260 of 359) with videos related to

Pageof 36
Sort By:
Nature Communications|September 13, 2023
CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s diseaseMarta Del Campo, Lisa Vermunt, Carel F W Peeters, et al.
Journal of Alzheimer'S Disease : JAD|September 5, 2017
The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical SettingEllis Niemantsverdriet, Julie Ottoy, Charisse Somers, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|July 27, 2019
Pre-analytical stability of novel cerebrospinal fluid biomarkersEline A J Willemse, Yannick Vermeiren, Maria-Salud Garcia-Ayllon, et al.
Proteomes|August 27, 2021
CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative IndividualsBetty Marije Tijms, Johan Gobom, Charlotte Teunissen, et al.
Journal of Alzheimer'S Disease : JAD|September 24, 2016
Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker TeamStephen P Arnerić, Richard Batrla-Utermann, Laurel Beckett, et al.
Frontiers in Neurology|September 9, 2015
A Practical Guide to Immunoassay Method ValidationUlf Andreasson, Armand Perret-Liaudet, Linda J C van Waalwijk van Doorn, et al.
Alzheimer'S Research & Therapy|July 8, 2018
The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristicsIsabelle Bos, Stephanie Vos, Rik Vandenberghe, et al.
BMC Public Health|January 31, 2018
Detecting frail, older adults and identifying their strengths: results of a mixed-methods studySarah Dury, Eva Dierckx, Anne van der Vorst, et al.
Nature|July 25, 2006
Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21Marc Cruts, Ilse Gijselinck, Julie van der Zee, et al.
Brain : a Journal of Neurology|December 18, 2015
Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohortSara Van Mossevelde, Julie van der Zee, Ilse Gijselinck, et al.
Pageof 36

Showing results (251-260 of 359) with videos related to

Sort By:
Pageof 36
Nature Communications|September 13, 2023
CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s diseaseMarta Del Campo, Lisa Vermunt, Carel F W Peeters, et al.
Journal of Alzheimer'S Disease : JAD|September 5, 2017
The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical SettingEllis Niemantsverdriet, Julie Ottoy, Charisse Somers, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|July 27, 2019
Pre-analytical stability of novel cerebrospinal fluid biomarkersEline A J Willemse, Yannick Vermeiren, Maria-Salud Garcia-Ayllon, et al.
Proteomes|August 27, 2021
CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative IndividualsBetty Marije Tijms, Johan Gobom, Charlotte Teunissen, et al.
Journal of Alzheimer'S Disease : JAD|September 24, 2016
Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker TeamStephen P Arnerić, Richard Batrla-Utermann, Laurel Beckett, et al.
Frontiers in Neurology|September 9, 2015
A Practical Guide to Immunoassay Method ValidationUlf Andreasson, Armand Perret-Liaudet, Linda J C van Waalwijk van Doorn, et al.
Alzheimer'S Research & Therapy|July 8, 2018
The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristicsIsabelle Bos, Stephanie Vos, Rik Vandenberghe, et al.
BMC Public Health|January 31, 2018
Detecting frail, older adults and identifying their strengths: results of a mixed-methods studySarah Dury, Eva Dierckx, Anne van der Vorst, et al.
Nature|July 25, 2006
Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21Marc Cruts, Ilse Gijselinck, Julie van der Zee, et al.
Brain : a Journal of Neurology|December 18, 2015
Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohortSara Van Mossevelde, Julie van der Zee, Ilse Gijselinck, et al.
Pageof 36